LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Therapeutic Targeting of Hypoxia-A2-Adenosinergic Pathway in COVID-19 Patients.

    Halpin-Veszeleiova, Katarina / Hatfield, Stephen M

    Physiology (Bethesda, Md.)

    2021  Volume 37, Issue 1, Page(s) 46–52

    Abstract: The hypoxia-hypoxia-inducible factor (HIF)-1α-A2-adenosinergic pathway protects tissues from inflammatory damage during antipathogen immune responses. The elimination of this physiological tissue-protecting mechanism by supplemental oxygenation may ... ...

    Abstract The hypoxia-hypoxia-inducible factor (HIF)-1α-A2-adenosinergic pathway protects tissues from inflammatory damage during antipathogen immune responses. The elimination of this physiological tissue-protecting mechanism by supplemental oxygenation may contribute to the high mortality of oxygen-ventilated COVID-19 patients by exacerbating inflammatory lung damage. Restoration of this pathway with hypoxia-adenosinergic drugs may improve outcomes in these patients.
    MeSH term(s) COVID-19 ; Humans ; Hypoxia ; Neoplasms ; Receptor, Adenosine A2A ; SARS-CoV-2
    Chemical Substances Receptor, Adenosine A2A
    Language English
    Publishing date 2021-09-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2158667-6
    ISSN 1548-9221 ; 1548-9213
    ISSN (online) 1548-9221
    ISSN 1548-9213
    DOI 10.1152/physiol.00010.2021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2164: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Oxygenation and A2AR blockade to eliminate hypoxia/HIF-1α-adenosinergic immunosuppressive axis and improve cancer immunotherapy.

    Halpin-Veszeleiova, Katarina / Hatfield, Stephen M

    Current opinion in pharmacology

    2020  Volume 53, Page(s) 84–90

    Abstract: The promising results of the first in-human clinical study using A2AR antagonists for treatment of renal cell carcinoma highlight two decades of research into the hypoxia-A2-adenosinergic pathway. Importantly, clinical responses have been observed in ... ...

    Abstract The promising results of the first in-human clinical study using A2AR antagonists for treatment of renal cell carcinoma highlight two decades of research into the hypoxia-A2-adenosinergic pathway. Importantly, clinical responses have been observed in patients who previously progressed on anti-PD-1/PDL-1 therapy, emphasizing the clinical importance of targeting A2AR signaling in cancer immunotherapies. Recently, it has been shown that systemic oxygenation weakens all known stages of the hypoxia-A2-adenosinergic axis. Therefore, we advocate the clinical use of systemic oxygenation and oxygenation agents in combination with A2AR blockade to further improve cancer immunotherapies. This approach is expected to completely eliminate the upstream (hypoxia-HIF-1α) and downstream (adenosine-A2AR) stages of the immunosuppressive hypoxia-adenosinergic signaling axis. This might be a necessary strategy to maximize the therapeutic benefits of A2AR antagonists and increase susceptibility of tumors to cancer treatments.
    MeSH term(s) 5'-Nucleotidase/immunology ; Adenosine/immunology ; Adenosine A2 Receptor Antagonists/therapeutic use ; Animals ; Antigens, CD/immunology ; Apyrase/immunology ; Humans ; Hypoxia-Inducible Factor 1, alpha Subunit/immunology ; Immune Tolerance ; Immunotherapy ; Neoplasms/immunology ; Neoplasms/therapy ; Oxygen/therapeutic use ; Receptor, Adenosine A2A/immunology ; Tumor Hypoxia
    Chemical Substances Adenosine A2 Receptor Antagonists ; Antigens, CD ; HIF1A protein, human ; Hypoxia-Inducible Factor 1, alpha Subunit ; Receptor, Adenosine A2A ; 5'-Nucleotidase (EC 3.1.3.5) ; Apyrase (EC 3.6.1.5) ; CD39 antigen (EC 3.6.1.5) ; Adenosine (K72T3FS567) ; Oxygen (S88TT14065)
    Language English
    Publishing date 2020-08-22
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2037057-X
    ISSN 1471-4973 ; 1471-4892
    ISSN (online) 1471-4973
    ISSN 1471-4892
    DOI 10.1016/j.coph.2020.07.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5608: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top